Holen Sie sich die Stockscreener-App
28.50
0.28%
0.08
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TGTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$28.42
Offen:
$28.65
24-Stunden-Volumen:
1.08M
Relative Volume:
0.58
Marktkapitalisierung:
$4.52B
Einnahmen:
$264.79M
Nettoeinkommen (Verlust:
$-14.36M
KGV:
-259.09
EPS:
-0.11
Netto-Cashflow:
$-28.11M
1W Leistung:
-1.25%
1M Leistung:
+2.26%
6M Leistung:
+2.26%
1J Leistung:
-7.26%
1-Tages-Spanne:
$28.28
$29.30
1-Wochen-Bereich:
$27.93
$30.00
52-Wochen-Spanne:
$25.28
$46.48
Tg Therapeutics Inc Stock (TGTX) Company Profile
Firmenname
Tg Therapeutics Inc
Sektor
Branche
Telefon
(212) 554-4484
Adresse
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
28.50 | 4.51B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2024-10-29 | Eingeleitet | TD Cowen | Buy |
| 2023-08-02 | Hochstufung | Goldman | Sell → Neutral |
| 2023-06-26 | Fortgesetzt | Jefferies | Buy |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2021-11-15 | Herabstufung | Goldman | Neutral → Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-19 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-01 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2018-09-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-04-25 | Eingeleitet | Jefferies | Buy |
| 2017-03-06 | Bestätigt | FBR & Co. | Outperform |
| 2016-10-06 | Fortgesetzt | Brean Capital | Buy |
| 2016-05-27 | Eingeleitet | SunTrust | Buy |
| 2015-12-01 | Eingeleitet | FBR Capital | Outperform |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-19 | Bestätigt | Brean Capital | Buy |
| 2014-12-11 | Bestätigt | ROTH Capital | Buy |
| 2014-12-10 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
What is TG Therapeutics Inc.’s valuation compared to sectorJuly 2025 Opening Moves & Verified Momentum Stock Ideas - mfd.ru
Goldman Sachs Raises TG Therapeutics, Inc. (TGTX) Target to $39 on 2026 Guidance - Finviz
TGTX News Today | Why did TG Therapeutics stock go down today? $TGTX - MarketBeat
Should you avoid TG Therapeutics Inc. stock right now2025 Sector Review & Free Risk Controlled Daily Trade Plans - mfd.ru
Why TG Therapeutics Inc. (NKB2) stock gets analyst attentionTrade Entry Report & Community Supported Trade Ideas - mfd.ru
10 Best Long Term Healthcare Stocks to Buy - Insider Monkey
TG Therapeutics (TGTX) sees price target drop from JPMorgan - MSN
Should New BRIUMVI Data and MS Campaign Shift TG Therapeutics' (TGTX) Narrative on Commercial Execution? - Yahoo Finance
TG Therapeutics Lights Up Super Bowl With Christina Applegate MS Campaign — Retail Sees 'Huge Win' - Stocktwits
MSFT Vs AMZN Vs GOOGL: Which Cloud Stock Is A Better Bet? - Stocktwits
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis - GlobeNewswire
Christina Applegate fronts new MS honesty campaign with TG Therapeutics - Stock Titan
TG Therapeutics Partners with Christina Applegate to Raise MS Awareness - intellectia.ai
TG Therapeutics (TGTX) Sees Price Target Drop from JPMorgan - Finviz
TG Therapeutics presents BRIUMVI data at ACTRIMS forum By Investing.com - Investing.com Nigeria
TG Therapeutics stock pops as Briumvi boom reignites bull case: Goldman Sachs sees room for 32% rally - MSN
TG Therapeutics Presents BRIUMVI Data at ACTRIMS Annual Meeting - Intellectia AI
TG Therapeutics presents BRIUMVI data at ACTRIMS forum - Investing.com
TG Therapeutics rises on new data for autoimmune therapy - TradingView
TG Therapeutics Presents New Data on BRIUMVI® at ACTRIMS 2026 Annual Forum - Quiver Quantitative
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum - The Manila Times
TG Therapeutics Announces Presentation of Data for BRIUMVI® - GlobeNewswire
Aug Intraday: Is TG Therapeutics Inc a turnaround story2025 Institutional Moves & AI Driven Stock Movement Reports - baoquankhu1.vn
Why (TGTX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
RSI Check: Should you avoid TG Therapeutics Inc stock right nowQuarterly Profit Summary & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
TG Therapeutics (NASDAQ:TGTX) Takes On Some Risk With Its Use Of Debt - 富途牛牛
TG Therapeutics stock maintains Buy rating at B.Riley on strong Briumvi growth - Investing.com Canada
Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares - AOL.com
JP Morgan Adjusts Price Target for TGTX, Maintains Overweight Ra - GuruFocus
JPMorgan Chase & Co. Issues Pessimistic Forecast for TG Therapeutics (NASDAQ:TGTX) Stock Price - MarketBeat
TG Therapeutics, Inc. (TGTX) Investor Outlook: Exploring the 52.42% Potential Upside and Strategic Positioning in Biotechnology - DirectorsTalk Interviews
Quarterly Trades: Will TG Therapeutics Inc benefit from AI trendsWeekly Gains Report & Fast Momentum Entry Tips - baoquankhu1.vn
Universal Beteiligungs und Servicegesellschaft mbH Has $2.29 Million Stake in TG Therapeutics, Inc. $TGTX - MarketBeat
TG Therapeutics Readies New BRIUMVI Data As Market Weighs Valuation - Sahm
Assessing TG Therapeutics (TGTX) Valuation After Recent Share Price Weakness And BRIUMVI Growth Assumptions - Yahoo Finance
TG Therapeutics to present BRIUMVI data at ACTRIMS forum By Investing.com - Investing.com Canada
TG Therapeutics to present BRIUMVI data at ACTRIMS forum - Investing.com
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum - The Manila Times
TG Therapeutics Highlights Upcoming BRIUMVI® Presentations at ACTRIMS 2026 Annual Forum - Quiver Quantitative
TG Therapeutics, Inc. (TGTX) Stock Analysis: A Biotech Powerhouse with 43.77% Potential Upside - DirectorsTalk Interviews
Understanding Momentum Shifts in (TGTX) - Stock Traders Daily
TG Therapeutics Achieves 8.54% Return; Birkenstock Reports -31.21% Loss - Markets Mojo
Analysts Conflicted on These Healthcare Names: Hinge Health, Inc. Class A (HNGE), Axsome Therapeutics (AXSM) and TG Therapeutics (TGTX) - The Globe and Mail
Is TG Therapeutics (TGTX) Pricing Reflecting Its Strong DCF And P/E Valuation Signals? - Sahm
Why TG Therapeutics (TGTX) Is Up 6.9% After Issuing 2026 BRIUMVI-Centric Revenue Guidance And What's Next - Sahm
Moving Averages: Should you avoid TG Therapeutics Inc stock right nowJuly 2025 Review & Fast Gain Stock Trading Tips - baoquankhu1.vn
TGTX rallies 8% after hours on revenue estimates based on strong Briumvi demand through 2026 - MSN
Finanzdaten der Tg Therapeutics Inc-Aktie (TGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):